Duchenne muscular dystrophy is a fatal muscle wasting disorder. Lack of dystrophin compromises the integrity of the sarcolemma and results in myofibres that are highly prone to contraction induced injury. rAAV mediated dystrophin gene transfer strategies to muscle for the treatment of DMD have been limited by the small cloning capacity of rAAV vectors and high titres needed to achieve efficient systemic gene transfer. Here we assess the impact of codon optimisation on microdystrophin (∆AB/R3-R18/∆CT) expression and function in the mdx mouse and compare the function of two different configurations of codon-optimised microdystrophin genes (∆AB/R3-R18/∆CT & ∆R4-R23/∆CT), under the control of a muscle restrictive promoter (Spc5-12). Codon optimisation of microdystrophin significantly increases levels of microdystrophin mRNA and protein following intramuscular and systemic administration of plasmid DNA or rAAV2/8. Physiological assessment demonstrates that codon optimisation of ∆AB/R3-R18/∆CT results in significant improvement in specific force, but does not improve resistance to eccentric contractions compared to non-codon-optimised ∆AB/R3-R18/∆CT. However, codon-optimised microdystrophin ∆R4-R23/∆CT completely restored specific force generation and provided substantial protection from contraction induced injury. These results demonstrate that codon optimisation of microdystrophin under the control of a muscle specific promoter can significantly improve expression levels such that reduced titres of rAAV vectors will be required for efficient systemic administration.
Abstract:
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Introduction:
Duchenne muscular dystrophy (DMD) is a severe muscle wasting disorder caused by a lack of dystrophin protein in skeletal muscle. Loss of dystrophin compromises the integrity of the muscle cell membrane and results in muscle fibres that are highly prone to contraction induced injury. Consequently there are progressive rounds of degeneration and regeneration of the muscle leading to the replacement of muscle fibres with non-contractile fibrotic tissue and fatty infiltrates. Recent reports have suggested that a minimum of 30% of normal dystrophin levels need to be present uniformly in all myofibres to prevent muscular dystrophy in humans, which is supported by data from transgenic mdx mice (1, 2). Efficient systemic gene transfer of dystrophin is crucial if restoration of muscle function is to be achieved.
Recombinant adeno-associated viral (rAAV) vectors are being investigated intensively for their potential to restore dystrophin expression in dystrophic muscle and thereby improve muscle function and stabilise or halt disease progression (3) (4) (5) (6) (7) . Two main hurdles exist in the use of rAAV vectors for DMD gene therapy; the packaging capacity of rAAV vectors and the very high titres of rAAV that have been required to achieve efficient systemic administration (6, 7) . To overcome the first issue, 'microgenes' encoding for truncated microdystrophin proteins have been engineered and tested rigorously in dystrophic mouse muscle (4, 8, 9) . A number of these microdystrophin proteins have been demonstrated to improve, but not completely normalise, a range of markers of the dystrophic phenotype. Restoration of the dystrophin associated protein complex (DAPC), stabilisation of muscle degeneration and improvements in muscle function have been demonstrated following delivery of microdystrophin at different stages of disease progression (6, 10, 11) . However, microdystrophin proteins are less able to protect dystrophic muscle from contraction induced injury (7, 8, 10) .
Secondly, although much progress has been made in the systemic delivery of rAAV microdystrophin vectors, this success has been achieved with the use of constitutive viral promoters driving gene expression and the injection of very high titres of rAAV.
Although such systems are invaluable in a research setting, it will be necessary to develop rAAV vectors that can achieve efficient gene transfer and expression at lower viral titres with a muscle restrictive promoter driving microdystrophin expression that will be more applicable for use in a clinical setting.
In this study, we tested the hypothesis that the optimisation of codon usage within the microdystrophin gene would result in increased levels of transgene expression such that the viral dose needed for effective reconstitution of dystrophin could be reduced. In contrast to treatment with non-codon-optimised rAAV2/8 microdystrophin, mdx mice treated with codon-optimised rAAV2/8 microdystrophin showed increased numbers of dystrophin positive fibres, improved muscle function and amelioration of dystrophic pathology. In addition, we demonstrate that systemic administration of codon-optimised rAAV2/8 microdystrophin under the control of a muscle restrictive promoter can result in skeletal muscle expression at doses of 3x10 11 vg/mouse (1x10 13 vg/kg).
Results:
Codon optimisation of microdystrophin increases mRNA and protein levels following plasmid gene transfer.
To assess the impact of codon optimisation on microdystrophin expression, plasmids expressing either non codon-optimised human ∆AB/R3-R18/∆CT, codon-optimised human ∆AB/R3-R18/∆CT or codon-optimised human ∆R4-R23/∆CT were transfected into HEK293T cells and total RNA was collected 48 hours post transfection. Quantitative RT-PCR demonstrates that microdystrophin mRNA levels are increased up to 30-fold (p<0.05) following transfection with codon-optimised constructs compared to the control plasmid (Figure 1a) . These plasmids were also tested in vivo by electrotransfer into the muscle of 6-8 week old mdx mice. Histological analysis of the tibialis anterior (TA) muscles at 7 days post injection demonstrates that treatment with a codon-optimised microdystrophin plasmid significantly increases the number of dystrophin positive fibres compared to a non codon-optimised microdystrophin (p<0.05). No difference is observed between codon-optimised ∆AB/R3-R18/∆CT and ∆R4-R23/∆CT when comparing levels of mRNA and dystrophin positive fibres (Figure 1a-b) . Electrotransfer with codon-optimised ∆AB/R3-R18/∆CT and ∆R4-R23/∆CT achieves robust staining of microdystrophin at the sarcolemma, although cytoplasmic staining of microdystrophin was observed with ∆R4-R23/∆CT but not with ∆AB/R3-R18/∆CT (Figure 1c-d) .
Codon optimisation of microdystrophin leads to efficient systemic gene transfer at low titres of rAAV2/8.
The impact of codon optimisation on rAAV based gene therapy was assessed, as despite the development of novel serotypes of rAAV, very high titres of rAAV are currently required to achieve efficient systemic gene transfer to the skeletal muscle (7, 12) . 3x10 11 vg of rAAV2/8 expressing either ∆AB/R3-R18/∆CT or codon-optimised ∆AB/R3-R18/∆CT and ∆R4-R23/∆CT was delivered via the tail vein of young adult mdx mice (10 weeks old). Cardiac and skeletal muscles were recovered at 12 weeks post treatment and assessed histologically. Microdystrophin is correctly localised to the sarcolemma and as has previously been demonstrated restores localisation of the DAPC. As was observed following electrotransfer much greater numbers of dystrophin positive fibres can be achieved following treatment with a codon-optimised construct compared to a control microdystrophin construct (∆AB/R3-R18/∆CT). However, unlike following electrotransfer, the number of dystrophin positive fibres observed following treatment with codonoptimised ∆R4-R23/∆CT is vastly superior to treatment with codon-optimised ∆AB/R3-R18/∆CT, with no evidence of cytoplasmic staining, making these treated muscles difficult to distinguish from wild type muscles (Figure 4a-h ). In accordance with these observations, central nucleation, a marker of myofibre regeneration, is normalised in muscles treated with codon-optimised ∆R4-R23/∆CT, but is not improved compared to mdx following treatment with AB/R3-R18/CT (Figure 5a ). Young adult mdx mice exhibit increased muscle mass compared to age matched controls; treatment with control rAAV2/8 ∆AB/R3-R18/∆CT has no effect on mass, whilst treatment with codonoptimised ∆AB/R3-R18/∆CT reduces TA mass significantly (p<0.05), but is still greater than wild type controls. However, administration of rAAV2/8 ∆R4-R23/∆CT reduces the mass of the mdx TA to such an extent that there is no significant difference to wild type muscle (p=0.8; Figure 5b ).
Delivery of rAAV2/8 codon-optimised microdystrophin leads to greater improvements in mdx muscle function.
Morphological changes in skeletal muscle of the mdx mouse are due to the lack of dystrophin and the deleterious effect that this has on muscle function. To test the ability of microdystrophin constructs to improve muscle function, we administered 7.5x10 9 vector genomes of a rAAV2/8 expressing either ∆AB/R3-R18/∆CT or codon-optimised ∆AB/R3-R18/∆CT or ∆R4-R23/∆CT under the control of the muscle specific promoter Spc5-12, into the TA muscle of 5 day old mdx mice. Mdx mice typically exhibit an increased maximal tetanic force, but a reduced specific force (force normalised for cross sectional area of the muscle) compared to age matched controls. Injection of rAAV2/8
∆AB/R3-R18/∆CT had no effect on either maximal tetanic or specific force compared to untreated mdx. However, specific force was significantly improved following treatment with codon-optimised rAAV2/8 ∆AB/R3-R18/∆CT (p<0.01), but was still reduced compared to wild type mice. In comparison, treatment with codon-optimised rAAV2/8
∆R4-R23/∆CT normalised maximal tetanic force, such that specific force was improved significantly compared to mdx mice (p<0.001), and showed no difference to the specific force generated by wild type mice (Figure 6a-c) .
In addition, we tested the ability of codon-optimised microdystrophins to protect mdx myofibres from exercise induced damage, by assessing maintenance of force production following a series of eccentric contractions. Treatment with either rAAV2/8 ∆AB/R3-R18/∆CT or the codon-optimised construct was unable to protect mdx muscle from force deficit induced by eccentric contractions (Figure 7) . However, treatment with codon-optimised rAAV2/8 ∆R4-R23/∆CT provided substantial protection from force deficit over a series of 10 eccentric contractions (compared to untreated mdx p<0.001).
In addition, the force deficit curve produced by muscles treated with codon-optimised ∆R4-R23/∆CT does not show a significant difference compared to the curve produced by wild type muscles (p=0.31; Figure 7 ).
Discussion:
This study has focused on the application of codon optimisation of a eukaryotic gene under the control of a muscle restrictive promoter to enhance gene expression and therefore functionality following plasmid and rAAV gene transfer. Both plasmid and rAAV gene transfer are being intensively investigated as potential therapeutic avenues for the treatment of DMD. Key to both these strategies is the ability to deliver the transgene efficiently to skeletal and cardiac muscle to produce robust levels of dystrophin expression under the control of a muscle restrictive promoter. In the case of rAAV, this must be achieved at viral doses that are not prohibitive. Here, we have optimised the codon usage of two different microdystrophin cDNA sequences and compared their expression and functionality to each other, and to a non-codon-optimised control.
Microdystrophin cDNA sequences were optimised in a number of ways to improve mRNA stability and translation efficiency. Sequences flanking the AUG start codon within an mRNA can influence its recognition by eukaryotic ribosomes. A consensus Kozak sequence has been shown to be important and required for the optimal translation of mammalian genes (13, 14) . A second point at which efficiency of translation can be improved is by optimisation of codon usage. Codon bias is observed in many species with the greatest deviation from random codon usage seen in highly expressed genes. Optimisation of codon usage for the species in which the transgene is expressed has resulted in significantly higher levels of protein expression, particularly when expressing viral proteins for genetic vaccination purposes (13, 15, 16) .
Microdystrophin cDNAs used in this study were modified to include a consensus Kozak sequence, codon usage was modified based on tRNA frequencies in human, and GC content was increased to promote mRNA stability (17) . We have demonstrated that by optimising the cDNA sequence of a eukaryotic gene for expression in a eukaryotic system, levels of mRNA can be significantly increased, as can the number of dystrophin positive fibres following intramuscular plasmid gene transfer and systemic rAAV gene transfer. This observation is in accordance with recent data which demonstrate optimised protein expression of eukaryotic genes through either incorporation of a Kozak sequence (18) or codon optimisation (19) .
Although mRNA levels from both codon-optimised constructs are equivalent, levels of protein expression seen following both plasmid and rAAV gene transfer was much higher with microdystrophin ∆R4-R23/∆CT than ∆AB/R3-R18/∆CT (through increased numbers of fibres and over expression within individual fibres). Transfection of skeletal muscle fibres with each of the microdystrophin constructs whether by viral or non-viral vectors should be equally efficient, and as mRNA production from both plasmids also appears to be equal, the difference in levels of protein expression may be attributed to protein stability. This is manifest at 1 week post electrotransfer as accumulation of microdystrophin R4-R23/CT within the cytoplasm of transfected fibres, although at this time point equal numbers of positive fibres were observed. By 8 weeks post rAAV gene transfer higher numbers of microdystrophin positive fibres are observed in the R4-R23/CT treated group compared to codon-optimised ∆AB/R3-R18/∆CT. This difference may be due to the loss of ∆AB/R3-R18/∆CT fibres over time as a result of lower bio-functionality of the protein or protein instability.
rAAV is a non-pathogenic, replication defective parvovirus, which is being extensively investigated as a gene delivery vehicle due to its apparent ability to exhibit prolonged transgene expression in the absence of an immune response. Many different serotypes of AAV have been described (20) (21) (22) . Of relevance to DMD are those which show very high tropism for skeletal and cardiac muscles and in particular are able to transduce these tissues following systemic administration. A number of groups have demonstrated this effect with rAAV serotypes 6, 8 and 9 (7, 12, 23, 24) . Although very dramatic levels of gene transfer were achieved in these studies, high titres of rAAV were required to achieve these levels of transduction (7). Scaling up these doses to larger animal models achieved good levels of expression in the heart, but very low levels of transduced fibres in skeletal muscle (12, 23) . In contrast to these studies, we demonstrate that we can achieve significant levels of microdystrophin expression in cardiac and skeletal muscles under the control of the muscle restrictive promoter Spc5-12 following an equivalent dose of rAAV2/8. It should be noted that this dose of rAAV2/8 did not achieve the body wide skeletal muscle gene expression previously demonstrated with much higher doses 
∆R4-R23/∆CT is based upon a microdystrophin described by the Chamberlain group (8).
This construct has previously been shown to be highly functional, demonstrating improvements in both muscle function and muscle pathology, following gene transfer to neonatal, young and old mdx mice (6, 7, 11, 27) . In comparable studies where mdx mice have been treated with rAAV as neonates (10, 27) , specific force and levels of central nucleation have been improved, with minimal improvements observed in resistance to eccentric contractions. Despite 10 fold fewer viral genomes being administered in the current study, we demonstrate complete normalisation of specific force and levels of central nucleation. We also demonstrate a substantial improvement in protection from eccentric contractions, using a protocol more physiologically relevant to the protocol employed by Banks et at (10) . As the rAAV microdystrophin vectors used by the Chamberlain group have essentially the same configuration including an optimal Kozak sequence (8), the improved outcome that we observe may be a reflection of the increased levels of dystrophin fibres and protein, as a result of codon optimisation and the use of highly efficient serotype rAAV2/8 vectors.
For the first time this study directly compares the functionality of two previously We conclude that optimisation of microdystrophin cDNA sequences for codon usage, GC content and the inclusion of optimal Kozak sequences, can significantly improve the outcome of gene transfer studies through maximising gene expression and protein levels. This system will be applicable to both viral gene transfer in allowing effective viral doses to be reduced and increasing the efficiency of vector production (19) , and also in improving efficiency of non viral gene transfer not only to muscle but across the whole field of gene therapy.
Materials and Methods:

Generation of constructs
Non codon-optimised human microdystrophin ∆AB/R3-R18/∆CT was constructed as previously described (4). Codon-optimised cDNA sequences of human and murine microdystrophins ∆AB/R3-R18/∆CT and ∆R4-R23/∆CT were generated by Geneart (Regensburg, Germany). These cDNA sequences, including an optimal Kozak sequence, were cloned into a pDD derived AAV plasmid (32) 
Tissue culture and qRT-PCR
HEK293T cells were grown and maintained in DMEM, 10%FCS at 8% CO 2 in a humidified incubator. Cells were seeded at a density of 1x10 4 cells/cm 2 in a 6 well plate and transfected with 4g plasmid DNA (p∆AB/R3-R18/∆CT, codon-optimised p∆AB/R3-R18/∆CT or p∆R4-R23/∆CT) using Lipofectamine 2000 (Invitrogen, Paisley, UK). All transfections were carried out in quadruplicate. Cells were harvested after 48 hours and RNA was extracted using an RNeasy Kit (Qiagen, Crawley, UK).
Total RNA (1μg) was reverse transcribed in a final volume of 25μl containing 5μl 5x RT buffer, 25U RNasin RNase inhibitor, 5μl 10mM dNTP, 200U M-MLV Reverse Transcriptase (Promega, Southampton, UK) and 2.5μM random nonamers (Sigma).
Reactions were incubated at 42C for 60 min and reverse transcriptase was inactivated by heating at 70C for 15 min and cooling at 4C for 5 min. 
Statistical Analysis
All data are presented as mean values SEM (cohort size stated per experiment). All statistical analysis was performed by one way ANOVA followed by Tukey-Kramer posthoc analysis. (1/50), or with haematoxylin and eosin. Scale bar = 300m 
